KALV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kalvista Pharmaceuticals Inc (KALV) is not a strong buy for a beginner, long-term investor at this moment. Despite positive analyst ratings and price target increases, the lack of recent positive news, significant insider and hedge fund selling, and weak technical and options data suggest caution. The stock's financial performance shows improvement in net income and EPS, but revenue growth remains stagnant. The absence of strong proprietary trading signals further supports a hold recommendation.
The technical indicators are mixed. The MACD is positive but contracting, RSI is neutral at 59.581, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock's candlestick pattern suggests a 66.67% chance of declining in the next day (-0.4%), week (-2.93%), and month (-40.01%). Key support and resistance levels are Pivot: 15.975, R1: 16.546, and S1: 15.404.
Analyst ratings are consistently positive, with multiple firms raising price targets to $29-$37 and maintaining Buy ratings. Analysts are optimistic about the company's oral therapy for hereditary angioedema and its potential market leadership.
Hedge funds and insiders are heavily selling, with hedge fund selling up 7382.63% and insider selling up 270.56%. No recent news or congressional trading data is available. The stock's candlestick pattern indicates a high probability of near-term declines.
In Q3 2025, revenue remained flat at $13.69M (0.00% YoY), while net income improved significantly to -$49.48M (up 70.46% YoY). EPS also improved to -0.92 (up 9.52% YoY). Gross margin remained strong at 91%. While profitability metrics are improving, stagnant revenue growth is a concern.
Analysts are bullish, with recent price target increases from TD Cowen ($35), Citizens ($29), H.C. Wainwright ($37), and Needham ($32). Analysts highlight the strong initial launch of Ekterly, its potential as a market leader, and attractive valuation. However, sustained demand remains uncertain.
